Non-alcoholic fatty liver disease (NAFLD) has become one of the main chronic liver
diseases worldwide. Protopanaxadiol (PPD), an active compound derived from …

Nonalcoholic fatty liver disease (NAFLD) is the most common type of liver disease in
developed countries. Oxidative stress plays a critical role in the progression of NAFLD …

Non-alcoholic fatty liver disease (NAFLD) has been a leading cause of chronic metabolic
disease, seriously posing healthy burdens to the public, whereas interventions available for …

Context Non-alcoholic fatty liver disease (NAFLD), the most common chronic liver disease,
can develop into metabolic associated fatty liver disease (MAFLD). Gypenosides (GP), the …

Background Triptolide is naturally isolated from Tripterygium wilfordii Hook F., possessing
multiple biological activities. Hepatotoxicity is one of the main side effects of triptolide …

Background Nonalcoholic fatty liver disease (NAFLD) is becoming a global epidemic without
effective treatment currently available. NAFLD is characterized by an increase in hepatic de …

Gypenosides (GP), extracted from the traditional Chinese herb Gynostemma pentaphyllum
(Thunb.) Makino, have been used to treat metabolic disorders, including lipid metabolism …

Background Non-alcoholic fatty liver disease (NAFLD) is a clinical pathological syndrome of
hepatic parenchymal cell steatosis caused by excessive lipid deposition, which is the …

Nonalcoholic fatty liver disease (NAFLD) is one of the most common liver diseases with
limited treatment options. Moreover, its prevalence is doubled in type 2 diabetes mellitus …

Background Metabolic associated fatty liver disease (MAFLD) is a progressive chronic liver
disease, yet there is still a lack of effective pharmacological therapies at present …